The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
FOCUS ARTICLE - WILL THIS TRIAL CHANGE MY PRACTICE?
Will LEADERS-FREE change my practice? A randomised double-blind comparison of the BioFreedom™ drug-coated stent vs. the Gazelle™ bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplatelet therapy
Giulio G. Stefanini1*, MD, PhD; Miles Behan2, MD; Marco Valgimigli3, MD, PhD; Keith G. Oldroyd4, MD; Martin B. Leon5, MD
1. Cardio Center, Humanitas Research Hospital, Rozzano - Milan, Italy; 2. Edinburgh Heart Centre, Royal Infirmary of Edinburgh and Roodlands Hospital, Haddington, United Kingdom; 3. Department of Cardiology, Bern University Hospital, Bern, Switzerland; 4.
Introduction to the session
The aim of the article is to capture the session at EuroPCR 2016, communicate the analysis of the trialist, and report the views expressed in the interactive discussion. The article does not constitute an independent review of the topic by the authors. The session focused on whether the LEADERS-FREE randomised trial will change clinical practice1.
Background: what was known before LEADERS-FREE
A large body of evidence consistently proved superiority of drug-eluting stents (DES) over bare metal stents (BMS) in terms of antirestenotic effectiveness2. In 2006, early-generation DES were associated with an increased risk of ...